New Data, New Directions: Neladalkib (NVL-655) and Precision Oncology in ALK-positive Cancer Sunday, March 1st at 7:00pm ET, Alexander Drilon, MD joined ALKtALK to present and discuss the latest data on neladalkib (NVL-655). The conversation included a review of emerging efficacy and safety data, along with discussion of how promising therapies move from clinical trials toward broader […]

